Top Markets
#1 DogBull DogBull +69.44%
#2 Siren Siren +31.70%
#3 OriginTrail OriginTrail +18.07%
#4 MarsCoin MarsCoin +9.72%
#5 Verus Coin Verus Coin +7.42%
#6 Falcon Finance Falcon Finance +6.32%
#7 RedStone RedStone +6.11%
#8 PulseChain PulseChain +6.04%
#9 Xphere Xphere +5.90%
#10 Concordium Concordium +5.69%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Cutia Therapeutics Cutia Therapeutics

Cutia Therapeutics

2487
Rank in Stocks #22318
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a... Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.
Share Price
$0.24945615
Last synced: 2026-08-21
Market Cap
$90.64M
Change (1 day)
-10.14%
Change (1 year)
-79.61%
Country
CN
Trade Cutia Therapeutics (2487)

Category

Healthcare
Revenue for Cutia Therapeutics (2487)
Revenue in Aug 2026 TTM: 0
According to Cutia Therapeutics latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Cutia Therapeutics from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH